This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lazar, A. J.F. Articles by Lev, D. Search for Related Content PubMed PubMed Citation Articles by Lazar, A. J.F. Articles by Lev, D.

Angiogenesis-Promoting Gene Patterns in Alveolar Soft Part Sarcoma

Authors' Affiliations: ¹ Sarcoma Research Center, and Departments of ² Pathology, ³ Surgical Oncology, and ⁴ Cancer Biology, ⁵ Division of Quantitative Sciences, The University of Texas M. D. Anderson Cancer Center, and ⁶ Department of Pathology, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas

Requests for reprints: Dina Lev, Department of Cancer Biology, Unit 1104, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-1637; Fax: 713-792-0722; E-mail: dlev{at}mdanderson.org.

Purpose: We examined a cohort of patients with alveolar soft part sarcoma (ASPS) treated at our institution and showed the characteristic ASPSCR1-TFE3 fusion transcript in their tumors. Investigation of potential angiogenesis-modulating molecular determinants provided mechanistic and potentially therapeutically relevant insight into the enhanced vascularity characteristic of this unusual tumor.

Experimental Design: Medical records of 71 patients with ASPS presenting at the University of Texas M.D. Anderson Cancer Center (1986-2005) were reviewed to isolate 33 patients with formalin-fixed paraffin-embedded material available for study. RNA extracted from available fresh-frozen and formalin-fixed paraffin-embedded human ASPS tumors were analyzed for ASPSCR1-TFE3 fusion transcript expression using reverse transcription-PCR and by angiogenesis oligomicroarrays with immunohistochemical confirmation.

Results: Similar to previous studies, actuarial 5- and 10-year survival rates were 74% and 51%, respectively, despite frequent metastasis. ASPSCR1-TFE3 fusion transcripts were identified in 16 of 18 ASPS samples. In the three frozen samples subjected to an angiogenesis oligoarray, 18 angiogenesis-related genes were up-regulated in tumor over adjacent normal tissue. Immunohistochemistry for jag-1, midkine, and angiogenin in 33 human ASPS samples confirmed these results. Comparison with other sarcomas indicates that the ASPS angiogenic signature is unique.

Conclusion: ASPS is a highly vascular and metastatic tumor with a surprisingly favorable outcome; therapeutically resistant metastases drive mortality. Future molecular therapies targeting overexpressed angiogenesis-promoting proteins (such as those identified here) could benefit patients with ASPS.

This article has been cited by other articles:

				Z. Jin, G. Lahat, B. Korchin, T. Nguyen, Q.-S. Zhu, X. Wang, A. J. Lazar, J. Trent, R. E. Pollock, and D. Lev Midkine Enhances Soft-Tissue Sarcoma Growth: A Possible Novel Therapeutic Target Clin. Cancer Res., August 15, 2008; 14(16): 5033 - 5042. [Abstract] [Full Text] [PDF]